Insulin treatment of individuals with type 1 diabetes has shortcomings and many patients do
not achieve glycaemic and metabolic targets. Consequently, the focus is on novel non …

Intensive insulin therapy is the mainstay of treatment for people with Type 1 diabetes, but
hypoglycaemia and weight gain are often limiting factors in achieving glycaemic targets and …

Insulin is a common treatment option for many patients with type 2 diabetes, and is generally
used late in the natural history of the disease. Its injectable delivery mode, propensity for …

Diabetes is a huge burden in China, where about 100 million people have been diagnosed
with the disease. Treatments are needed that are optimal for treating Chinese patients with …

Diabetes Control and Complications Trial (DCCT). This important question, and many others
about the efficacy of available treatments in NIDDM, should be answered in 1995 when the …

Drug therapy for non-insulin-dependent diabetes mellitus (NIDDM) is far from ideal.
Sulphonylureas have been the mainstay of oral hypoglycaemic treatment for over 30 years …

Medical care for people with diabetes has become increasingly expensive. In the USA, the
total cost of diagnosed diabetes in 2012 was an estimated $245 billion, up by 21% from …

Two opposing principles clash when physicians consider management issues for patients
with type 2 diabetes: primum succurere, first hasten to help; and primum non nocere, first do …

reliable than the much condemned impact factors for journals. 5–7 Also, related publications
will be easier to find once they are coded with a unique researcher identifier, not only from …

The pathogenesis of type 1 diabetes initiates years before the clinical diagnosis.
Progressive immune attack decreases β-cell mass, leading to dysglycaemia and insulin …